Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S.-Iran talks collapsed after a planned envoy mission was canceled, prolonging Strait of Hormuz disruptions.
  • Strait of Hormuz disruptions have pushed energy prices to multi-year highs and raised global inflation and growth risks.
  • Major central banks signaled a tactical pause as energy shocks make inflation paths uncertain.
  • Goldman Sachs revised FX and growth forecasts, cutting USD/BRL and flagging terms-of-trade effects on currencies.
  • Global retailers face rising customer-acquisition costs, prompting higher marketing spend and potential margin pressure.
  • Ukraine marked 40 years since Chornobyl amid reports of repeated Russian drones and missile flights near the plant.

Latest Articles

Eldorado Gold Reminds Shareholders to Vote FOR the Share Issuance Resolution and Foran Mining Reminds Securityholders to Vote FOR the Arrangement Resolution
Mar 31, 2026
Derek Hwang
Press Releases

Eldorado Gold Reminds Shareholders to Vote FOR the Share Issuance Resolution and Foran Mining Reminds Securityholders to Vote FOR the Arrangement Resolution

Eldorado Gold Corporation and Foran Mining Corporation announced upcoming shareholder meetings for approval of a proposed plan of arrangement wherein Eldorado will acquire Foran, making it a wholly-owned subsidiary. The combined entity aims to leverage Eldorado's financial strength and operational platform with Foran's copper growth projects, targe…

ELD, EGO, FOM, FMCXF
Lightbridge Receives Notice of Allowance on New U.S. Patent for its Metallic Fuel Assemblies for CANDU Reactors
Mar 31, 2026
Nina Shah
Press Releases

Lightbridge Receives Notice of Allowance on New U.S. Patent for its Metallic Fuel Assemblies for CANDU Reactors

Lightbridge Corporation announced receiving a Notice of Allowance from the USPTO for a new U.S. patent covering its advanced spirally twisted, multi-lobed metallic fuel assemblies designed for pressurized heavy-water reactors including CANDU-type designs. This strengthens their intellectual property portfolio for their advanced nuclear fuel technol…

LTBR
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Mar 31, 2026
Maya Rios
Press Releases

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

BioXcel Therapeutics announced that the FDA has accepted its supplemental New Drug Application for IGALMI® to be used in the at-home setting to acutely treat agitation associated with bipolar disorders or schizophrenia. The FDA set a PDUFA action date of November 14, 2026. This approval could introduce the first FDA-approved at-home treatment for a…

BTAI
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Mar 31, 2026
Maya Rios
Press Releases

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Ocular Therapeutix, Inc. announced plans to present new data from their Phase 3 clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at upcoming scientific conferences in April 2026. The presentations aim to highlight the drug's efficacy and support its therapeutic potential, with sessions scheduled at the Vit-Buckle Society…

OCUL
FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results
Mar 31, 2026
Jordan Park
Press Releases

FitLife Brands Announces Fourth Quarter and Full-Year 2025 Results

FitLife Brands announced its Q4 and full-year 2025 financial results highlighting a 73% increase in Q4 revenue and a 26% increase for the full year, largely fueled by the recent acquisition of Irwin Naturals. Despite growth in total and wholesale revenues, gross margins declined due to Irwin's historically lower margins and amortization expenses. N…

FTLF
Telix Appoints David Gill as Non-Executive Director
Mar 31, 2026
Ajmal Hussain
Press Releases

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals Limited announced the appointment of David Gill as a Non-Executive Director effective May 11, 2026, with expectations that he will become Chair, succeeding Dr. Mark Nelson. Gill brings over 35 years of biotech and medical device leadership experience, including expertise in U.S. capital markets, positioning Telix for stronger …

TLX
Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year
Mar 31, 2026
Sofia Navarro
Press Releases

Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year

Tilray Brands, Inc. reported record third quarter fiscal 2026 results driven by 11% net revenue growth to $207 million and a 6% increase in gross profit to $55 million. The company exhibited strong international cannabis revenue growth of 73% year-over-year, solidifying its leadership in the Canadian cannabis market. The recent acquisition of BrewD…

TLRY
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Mar 31, 2026
Leila Farooq
Press Releases

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

Rapport Therapeutics announced it will present new 8-week follow-up data from its Phase 2a trial of RAP-219, a novel targeted treatment for focal onset seizures, at the 2026 American Academy of Neurology Annual Meeting. RAP-219 specifically modulates the TARP-γ8 AMPA receptor subunit, potentially offering improved efficacy and tolerability for neur…

RAPP
RenX Enterprises Corp. Beats Revenue Guidance, Delivering $8.2 Million in Post-Acquisition Revenue While Completing Full Platform Buildout and Retiring $11.9 Million in Legacy Debt
Mar 31, 2026
Nina Shah
Press Releases

RenX Enterprises Corp. Beats Revenue Guidance, Delivering $8.2 Million in Post-Acquisition Revenue While Completing Full Platform Buildout and Retiring $11.9 Million in Legacy Debt

RenX Enterprises Corp. reported fiscal year 2025 financial results, highlighting $8.2 million in post-acquisition revenue—17% above guidance—after acquiring Resource Group US Holdings LLC. The company completed the buildout of its Myakka City biomass processing facility, initiated deliveries into the premium compost market, retired $11.9 million in…

RENX
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Mar 31, 2026
Derek Hwang
Press Releases

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics announced participation at the 2026 AMCP Conference with presentations on clinical trial data supporting their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) therapeutics. The company is preparing for potential U.S. launches of DMD treatment next year and DM1 treatment in early 2028, focusing on payer engage…

DYN
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Mar 31, 2026
Ajmal Hussain
Press Releases

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma Ltd. provided clarification on its Phase 2 clinical trial data for SkinJect, a doxorubicin-containing microneedle array for nodular basal cell carcinoma treatment. The company emphasized the therapeutic importance of the active drug arms over the device-only arm, highlighting that the 200µg dose cohort demonstrated the most promising…

MDCX
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
Mar 31, 2026
Priya Menon
Press Releases

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

MiNK Therapeutics announced that an abstract on its investigational allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, has been accepted for presentation at the 2026 American Thoracic Society International Conference. The presentation will highlight a novel combination immunotherapy approach targeting severe and persistent infect…

INKT
Anterix and Texas-New Mexico Power Agreement Bolsters Grid Resiliency with Proven 900 MHz Private Wireless Platform
Mar 31, 2026
Leila Farooq
Press Releases

Anterix and Texas-New Mexico Power Agreement Bolsters Grid Resiliency with Proven 900 MHz Private Wireless Platform

Anterix has entered into a 900 MHz spectrum sale agreement with Texas-New Mexico Power (TNMP) to enable deployment of a mission-critical private wireless network aimed at improving grid reliability and outage response. This collaboration supports TNMP's System Resiliency Plan and aligns with a broader trend of Texas utilities adopting secure privat…

ATEX
Crane NXT Completes Acquisition of Antares Vision
Mar 31, 2026
Sofia Navarro
Press Releases

Crane NXT Completes Acquisition of Antares Vision

Crane NXT, Co. finalized the acquisition of Antares Vision S.p.A., a leading company in detection, inspection, and traceability technologies. This acquisition broadens Crane NXT's portfolio, especially targeting the ~$3 billion life sciences and food & beverage sectors. Antares Vision has been delisted from Euronext Milan and is now a wholly owned …

CXT
Watsco Declares $3.30 Quarterly Dividend
Mar 31, 2026
Jordan Park
Press Releases

Watsco Declares $3.30 Quarterly Dividend

Watsco, Inc. has declared a $3.30 quarterly dividend, a 10% increase leading to an annual rate of $13.20 per share, payable April 30, 2026. The dividend hike signals confidence in Watsco's strong balance sheet and ongoing growth prospects in the North American HVAC/R distribution market. The company has a 52-year history of paying dividends and is …

WSO
New Home Sites Released at Monterey at Lakewood Ranch by Toll Brothers
Mar 31, 2026
Hana Yamamoto
Press Releases

New Home Sites Released at Monterey at Lakewood Ranch by Toll Brothers

Toll Brothers Inc., a leading U.S. builder of luxury homes (NYSE:TOL), announced a new phase of home sites available at Monterey at Lakewood Ranch in Florida. The community offers highly customizable single-family homes with resort-style amenities launching in fall 2027, targeting affluent buyers seeking sophisticated living in a premier location. …

TOL
Treasure Global’s Subsidiary Tadaa Technologies Partners with Anhui Fuyuan Group to Accelerate Global Drone and Electric Mobility Expansion
Mar 31, 2026
Sofia Navarro
Press Releases

Treasure Global’s Subsidiary Tadaa Technologies Partners with Anhui Fuyuan Group to Accelerate Global Drone and Electric Mobility Expansion

Treasure Global Inc., a tech company listed on NASDAQ, announced a strategic partnership between its subsidiary Tadaa Technologies and Anhui Fuyuan Electromechanical Technology Co. Ltd. The partnership aims to establish a Malaysia-based hub focused on electric mobility solutions and military-grade drones targeting markets in Europe, North America, …

TGL
VivoSim Announces Pricing of up to a $4 Million Public Offering
Mar 31, 2026
Priya Menon
Press Releases

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Labs, a Nasdaq-listed biotech company specializing in next-generation New Approach Methodologies (NAMs) for preclinical safety testing using 3D human tissue models, has announced the pricing of a $4 million public offering. The offering comprises an initial $3 million closing and an additional $1 million tranche contingent on conditions suc…

VIVS